Advanced search
Publication Cover
Bioanalysis Volume 13, 2021 - Issue 17
Submit an article Journal homepage
68
Views
0
CrossRef citations to date
0
Altmetric
Methodology

Quantitation of Vistusertib by UHPLC-MS/MS in Rat Plasma and its Application to a Pharmacokinetic Study

Fuqi Wang1 School of Traditional Chinese Material Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
,
Danni Song1 School of Traditional Chinese Material Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
,
Fengmao Zou1 School of Traditional Chinese Material Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
,
Honghui Zhao2 Faculty of Functional Food & Wine, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
&
Xu Zhao2 Faculty of Functional Food & Wine, Shenyang Pharmaceutical University, Shenyang, 110016, PR ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8537-1414
ORCID Icon
Pages 1333-1341 | Received 07 Jul 2021, Accepted 25 Aug 2021, Published online: 02 Sep 2021

Reference

  • Pike KG , MalaguK, HummersoneMGet al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg. Med. Chem. Lett.23(5), 1212–1216 (2013).
  • Guichard SM , CurwenJ, BihaniTet al. AZD2014, an Inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Mol. Cancer Ther.14(11), 2508–2518 (2015).
  • Liao H , HuangY, GuoBet al. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. Am. J. Cancer Res.5(1), 125–139 (2015).
  • Liao HF , LinYZ, YuCCet al. mTORC1/2 inhibitor served as a more ideal agent against the growth of mouse lymphocytic leukemia both in vitro and in vivo. Anticancer Res.39(9), 4829–4835 (2019).
  • Jones AT , YangJ, NarovKet al. Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of Tsc2(+/−) mice. Neoplasia21(8), 731–739 (2019).
  • Milosevic Z , BankovicJ, DinicJet al. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma. Cell Oncol. (Dordr.)41(4), 409–426 (2018).
  • Wong Te Fong AC , ThavasuP, GagricaSet al. Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. Oncotarget8(69), 113874–113884 (2017).
  • Basu B , KrebsMG, SundarRet al. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann. Oncol.29(9), 1918–1925 (2018).
  • Querfurth H , LeeHK. Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol. Neurodegener.16(1), 44 (2021).
  • Bensalem J , FourrierC, HeinLKet al. Inhibiting mTOR activity using AZD2014 increases autophagy in the mouse cerebral cortex. Neuropharmacology190, 108541 (2021).
  • MacCallum PE , BlundellJ. The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory. Psychopharmacology237(9), 2795–2808 (2020).
  • Lapointe S , MasonW, MacNeilMet al. A Phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Invest. New Drugs38(4), 1137–1144 (2020).
  • Eyre TA , HildyardC, HamblinAet al. A Phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. Hematol. Oncol.37(4), 352–359 (2019).
  • Schmid P , ZaissM, Harper-WynneCet al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the MANTA Phase 2 randomized clinical trial. JAMA Oncol.5(11), 1556–1563 (2019).
  • Basu B , DeanE, PuglisiMet al. First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clin. Cancer Res.21(15), 3412–3419 (2015).
  • MacDonald A , ScarfeG, MagirrDet al. Phase I study of orally administered (14)Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies. Cancer Chemoth. Pharm.83(4), 787–795 (2019).
  • Department of Health and Human Services Food and Drug Administration. Guidance for Industry - Bioanalytical Method Validation (2018). https://www.fda.gov/media/70858/download
  • Fang L , ZhouC, JiangMet al. Development of a ultra-performance LC-MS/MS method for quantification of GW788388 and its applications in pharmacokinetic study in rats. Bioanalysis12(23), 1681–1688 (2020).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.